Ovarian Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 20 – Jul 27, 2026
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
Phase 1/2 IMC-C103C-101 (NCT03973333) evaluated the safety, PK/PD, biomarkers, and preliminary antitumor activity of the MAGE-A4×CD3 ImmTAC IMC‑C103C in HLA‑A*02:01 adults with previously treated advanced solid tumors via weekly IV step‑up dosing and mTPI‑2–guided dose escalation. Sixty‑eight patients (56 in 10 dose‑escalation cohorts, 12 in an ovarian carcinoma expansion; 64% OC) received 0.5–240 µg; DLT rates at the two highest dose levels were 1/6 and 2/10, with no treatment‑related discontinuations or deaths. A 15‑45‑140 µg regimen was selected for expansion, with mainly grade 1/2 cytokine‑mediated adverse events including CRS; 71% of tumors were MAGE‑A4+, median H‑score 16. Clinical and PD activity began at 15 µg and was more consistent at ≥90 µg, where MAGE‑A4+ OC showed deeper tumor and ctDNA reductions and a trend toward longer overall survival; IMC‑C103C was well tolerated up to 140 µg.
10.1136/jitc-2025-014638
Jul 06 – Jul 13, 2026
Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.
INT J GYNECOL CANCER · Q1 JOURNAL - RANK #8/140
The NUVOLA trial evaluated the feasibility and efficacy of adding olaparib to neoadjuvant chemotherapy in 36 patients with newly diagnosed BRCA-mutated advanced epithelial ovarian cancer. This open-label, single-arm phase II study administered weekly carboplatin and paclitaxel with intermittent olaparib, targeting a primary endpoint of complete pathological response (achieved in 8.6% of patients) and secondary endpoints including an 89% overall response rate and median progression-free survival of 39.7 months. Treatment-related adverse events occurred in 86% of patients, with 58% requiring dose reductions and 11% discontinuing treatment. The study concluded that concurrent olaparib with neoadjuvant chemotherapy did not significantly improve complete pathological response, suggesting its benefit may lie primarily in post-chemotherapy maintenance.
10.1016/j.ijgc.2026.104816
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.
BRIT J CANCER · Q1 JOURNAL - RANK #47/326
This single-arm phase 2 trial evaluated olaparib 300 mg orally twice daily in 22 patients with platinum-sensitive relapsed high-grade serous ovarian cancer (HGSOC) and metastatic triple-negative breast cancer (mTNBC) harboring non-germline BRCA homologous recombination deficiency (HRD). Tumor methylation (BRCA1/RAD51C) and non-BRCA HR gene mutations were analyzed with high-resolution melting PCR and targeted sequencing, with promoter methylation detected in 8/15 HGSOC and 5/7 TNBC. The 6-month objective tumor response rate (OTRR) was 40% in HGSOC (6/15) and 0% in mTNBC (0/7), while 6-month/12-month progression-free survival (PFS) rates were 53%/25% for HGSOC and 17%/0% for mTNBC. Olaparib demonstrated encouraging activity in HGSOC beyond germline BRCA1/2 mutations, but showed limited efficacy in pre-treated mTNBC.
10.1038/s41416-026-03535-6
Jun 29 – Jul 06, 2026
Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.
SIGNAL TRANSDUCT TAR · Q1 JOURNAL - RANK #1/319TOP-TIER
NAIVE was a prospective phase II trial in FIGO IIIC–IV epithelial ovarian cancer comparing neoadjuvant platinum chemotherapy plus tislelizumab (NACI) to chemotherapy alone (NAC), with 1-year PFS as the primary endpoint and secondary efficacy/safety outcomes; immune profiling (scRNA-seq, CyTOF) explored mechanisms. Among 25 patients (median follow-up 30.7 months), NACI showed median PFS 27.2 vs 21.8 months (HR 0.44, 95% CI 0.15–1.26; P=0.127), 1-year PFS 92.3% vs 83.3%, 2-year PFS 62.3% vs 31.8%, and higher ORR (69.2% vs 58.3%), with more R0 resections and CRS3. No unexpected safety signals occurred; immune-related adverse events were manageable. Authors conclude NACI yields a nonsignificant PFS advantage and identify a CXCL13 Th1–GC B cell–TLS axis linked to response.
10.1038/s41392-026-02746-w
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
The study reports updated patient-reported outcomes (PROs) and evaluates the impact of disease progression on health-related quality of life (HRQOL) in the PRIMA/ENGOT-OV26/GOG-3012 trial, a randomized 2:1 trial comparing niraparib first-line maintenance therapy to placebo in newly diagnosed advanced ovarian cancer. HRQOL was assessed using EORTC QLQ-C30, QLQ-OV28, FOSI, and EQ-VAS, with post hoc analyses showing questionnaire completion rates exceeding 89% through cycle 24 and 80% at treatment end. Disease progression led to sustained HRQOL deterioration, with significant reductions in EORTC QLQ-C30 overall HRQOL, FOSI, and EQ-VAS scores, while niraparib did not negatively affect HRQOL compared to placebo. The findings underscore the clinical importance of prolonging progression-free survival to maintain HRQOL in ovarian cancer patients.
10.1016/j.ygyno.2026.06.010
A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This pilot phase II neoadjuvant study evaluated fulvestrant plus abemaciclib in women with advanced, unresectable low-grade serous ovarian carcinoma, with imaging every 8 weeks and clinical benefit rate (CBR) as the primary endpoint; exploratory safety and multi-omic biomarker analyses were performed. Fifteen patients were evaluable; CBR was 100%, comprising 1/15 complete response (7%), 8/15 partial responses (53%), and 6/15 stable disease (40%). Interval cytoreductive surgery was performed in 9/15 (60%), with 7/9 (78%) achieving complete or optimal resection; treatment was well tolerated. Transcriptomic/proteomic profiling (n=14) showed higher baseline cell-cycle and estrogen-signaling activity in long-term survivors that was suppressed on treatment, suggesting predictive biomarkers; overall, the regimen induced high response rates and facilitated optimal surgery.
10.1038/s41467-026-74571-2
Jun 08 – Jun 15, 2026
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This prospective, first-in-human Phase I trial assessed the oral CDC2-like kinase inhibitor rogocekib (CTX-712) in 46 adults with advanced, relapsed, or refractory solid tumors. Using an accelerated titration followed by a 3 + 3 dose-escalation (10–175 mg twice weekly) and three dose-expansion cohorts (105 mg BIW, 70 mg BIW, 105 mg QW), investigators determined the maximum tolerated dose at 140 mg BIW and identified dose-limiting toxicities of thrombocytopenia with hypokalemia and dehydration. Pharmacokinetics were dose-proportional, and pharmacodynamic assays (THAP9-AS1, S6K) indicated target engagement; partial responses occurred in 3/46 patients (6.5 %), all with ovarian cancer. Despite two treatment-related deaths, most adverse events (chiefly nausea, vomiting, diarrhea) were manageable, supporting further clinical development of rogocekib.
10.1158/1078-0432.CCR-25-4896
May 25 – Jun 01, 2026
PiggyBac-engineered membrane-bound IL-7 TILs combined with anti-PD-1 antibody demonstrates efficacy in recurrent ovarian cancer: a first-in-human phase 1 trial.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This first-in-human phase 1 clinical trial evaluated the safety, tolerability, and efficacy of the GC203 regimen, which combines piggyBac-engineered membrane-bound IL-7 (mbIL-7) autologous tumor-infiltrating lymphocytes (TILs) with an anti-PD-1 antibody, in 18 heavily pretreated recurrent ovarian cancer (rOC) patients. Participants underwent lymphodepletion followed by GC203 infusion, and treatment-related adverse events were predominantly transient and hematologic (57% had grade ≥3 lymphopenia and neutropenia). Results showed an unconfirmed objective response rate (ORR) of 33.3% and a disease control rate (DCR) of 83.3%, with a median progression-free survival (PFS) of 7.2 months and overall survival (OS) of 17.1 months. Exploratory analysis revealed that the Morisita Overlap Index (MOI) predicted treatment response, supporting further development of GC203 for rOC management.
10.1158/1078-0432.CCR-25-4130
Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial.
J OVARIAN RES · Q1 JOURNAL - RANK #6/42
This study aimed to evaluate overall survival and long-term safety of olaparib maintenance therapy in Asian patients with platinum-sensitive recurrent ovarian cancer (PSROC). As a prospective, open-label, single-arm, Phase IIIb clinical trial, it followed patients taking oral olaparib (300 mg twice daily) until disease progression or unacceptable toxicity, with a median follow-up of 73.4 months. The median overall survival (mOS) reached 51.0 months (95% CI: 42.7–56.1), with subgroup analysis showing mOS of 64.4 months (BRCA-mutated) and 40.9 months (BRCA wild-type). Long-term safety data revealed no new safety concerns, with 1.3% experiencing myelodysplastic syndrome or acute myeloid leukemia (MDS/AML).
10.1186/s13048-026-02144-4